Latest News and Press Releases

– Successfully licensed helicase-primase inhibitor program for recurrent genital herpes to Gilead, including candidates ABI-5366 and ABI-1179, following positive Phase 1b interim data; development...

BOISE, Idaho, March 18, 2026 (GLOBE NEWSWIRE) -- Micron Technology, Inc. (Nasdaq: MU) today announced results for its second quarter of fiscal 2026, which ended February 26, 2026. Fiscal Q2 2026...

SEATTLE and VANCOUVER, British Columbia, March 17, 2026 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage specialty pharmaceutical company focused on the global...

COPENHAGEN, Denmark – March 16, 2026. Novonesis has completed a EUR 1.7 billion bond issuance, with significant interest from a broad group of investors. The transaction was primarily undertaken to...

XOMA Royalty will conduct a webcast to review 4Q and full year 2025 financial results

TORONTO, 11 mars 2026 (GLOBE NEWSWIRE) -- Le Conseil canadien sur la reddition de comptes (CCRC) a publié ses premiers rapports d’inspection de chaque cabinet, marquant ainsi une étape importante...

CPAB has published its first individual firm inspection reports, marking a significant milestone in the evolution of CPAB’s public disclosure practices.

Enrollment for the OCU400 Phase 3 liMeliGhT clinical trial—the first and largest gene therapy registrational trial for broad retinitis pigmentosa patients—was completed. Topline Phase 3 data expected...

2025 Net Income of $35.4 million, EBITDA1 of $89.8 million and Free Cash Flow to Equity1 of $37.1 million18th Quarterly Dividend of Cdn$0.04 Declared$20.4 million Returned to Shareholders in...

COPENHAGEN, Denmark – February 26, 2026. Novonesis delivered strong organic sales growth of 7% and an adjusted EBITDA margin of 37.1% in 2025. The company expects a good start to 2026 and a good year...